Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855997 | 0.93 | HPGD (0.48) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL358661 | 0.89 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL17163075 | 0.89 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL15797058 | 0.89 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL10290907 | 0.87 | USP2 (0.55) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL21145481 | 0.86 | HPGD (0.55) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL3436829 | 0.85 | USP2 (0.56) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL8254018 | 0.84 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| Methane SCHEMBL27676530 | 0.84 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL78071 | 0.83 | USP2 (0.55) | USP2SMN1; SMN2HPGDEPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4688738-A1 | HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688742-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-3891149-B1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
| US-20040224978-A1 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
| US-20040209948-A1 | CCR8 Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004089312-A2 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004058709-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058736-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| EP-1235825-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | USP2 2291/4885SMN1; SMN2 4785/4885HPGD 987/4885 |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | HTR5A, HTR2C, HTR1A | USP2 3793/4885SMN1; SMN2 1418/4885HPGD 655/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | USP2 1115/4885SMN1; SMN2 1443/4885HPGD 2049/4885 |
| US-20040209948-A1 | CCR8 Inhibitors | CCR8, CCR1, CCR3 | USP2 2042/4885SMN1; SMN2 3175/4885HPGD 1350/4885 |
| US-20040224978-A1 | CCR8 inhibitors | CCR8, CCR1, CCRL2 | USP2 2097/4885SMN1; SMN2 2454/4885HPGD 1313/4885 |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | USP2 4210/4885SMN1; SMN2 4611/4885HPGD 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.